A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer

Table 3 Median TTP and OS by treatment arm.

	Treatment Group
	DC (n = 67)	D (n = 65)
Median PFS (mo)	3.33	2.60	P = 0.012 (Log-Rank test)
Min - Max	0.2 - 23.0	0.5 - 17.8
95% CI	(2.59 - 4.07)	(1.74 - 3.46)
1-year with no progression	11.6%	5.4%
Median survival (months)	10.27	7.70	P = 0.550 (Log-Rank test)
Min - Max	0.7 - 36.8	0.5 - 43.2
95% CI	(7.07 - 13.47)	(3.39 - 12.01)
1-year survival Kaplan-Meier estimate (%)	43.8%	40.3%

ISSN: 1471-2407